Cefuroxime Capsules

This product is a first-generation cephalosporin, which has good antibacterial effect on some strains of Gram-positive cocci such as non-penicillinase-producing and penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, group A hemolytic Streptococcus, Streptococcus pneumoniae and viridans Streptococcus. Anaerobic Gram-positive bacteria are mostly sensitive to this product, while Bacteroides fragilis is resistant to it. Methicillin-resistant Staphylococci and Enterococci are resistant to this product. The effect of this product on Gram-positive and Gram-negative bacteria is similar to that of cephalexin. This product has a certain effect on Neisseria gonorrhoeae, and is also active against enzyme-producing Neisseria gonorrhoeae; its activity against Haemophilus influenzae is poor.

The main ingredient of this product is cefradine, and its chemical name is (6R,7R)-7[(R)-2-amino-2-(1,4-cyclohexenyl)acetylamino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid. Molecular formula: C16H19N3O4S Molecular weight: 349.40

This product is a capsule, and the contents are white to off-white or light yellow powder or granules.

It is suitable for acute pharyngitis, tonsillitis, otitis media, bronchitis, pneumonia and other respiratory tract infections, urogenital tract infections and skin and soft tissue infections caused by sensitive bacteria. This product is an oral preparation and should not be used for severe infections.

Common oral dosage for adults: 0.25-0.5g (1-2 tablets) once, once every 6 hours (4 times a day). For patients with more serious infections, the dosage can be increased to 1g (4 tablets) once, but the total daily dosage should not exceed 4g (16 tablets). Common oral dosage for children: 6.25-12.5mg/kg per child, once every 6 hours (4 times a day).

The adverse reactions of this product are relatively mild and the incidence is also low, about 6%. 1. Gastrointestinal reactions such as nausea, vomiting, diarrhea, and upper abdominal discomfort are relatively common. 2. The incidence of drug rash is about 1% to 3%. 3. Pseudomembranous colitis, eosinophilia, positive reaction to direct Coombs test, peripheral blood leukocyte and neutrophil decrease are seen in individual patients. 4. A small number of patients may experience temporary increase in blood urea nitrogen, serum aminotransferase, and serum alkaline phosphatase.

This product is contraindicated in patients who are allergic to cephalosporins or have a history of anaphylactic shock or immediate reaction to penicillin.

Precautions for children: Adverse reactions reported after domestic marketing indicate that the use of this product may cause hematuria. Children are susceptible to the disease, so patients with renal impairment and children should use this product with caution and under monitoring. Precautions for pregnancy and lactation: This product can enter the fetal blood circulation through the placental barrier and can also enter breast milk. Pregnant and lactating women should use it with caution. Precautions for the elderly: Elderly patients with renal impairment should appropriately reduce the dose or extend the dosing interval.

1. Cephalosporins can delay the excretion of phenytoin sodium in the renal tubules. 2. Phenylbutazone combined with cephalosporin antibiotics can increase renal toxicity. 3. Combined with strong diuretics can increase renal toxicity. 4. Combined with mecillinam, it has a synergistic effect on Gram-negative rods such as Escherichia coli and Salmonella. 5. Probenecid can delay the excretion of this product.

Seal tightly and store in a cool, dark place.

0.25 g

24 months.

Yili Pharmaceutical Co., Ltd.

• Founded in:

  2008-12-26

• Address:

  Fengshan Road, Dongcheng District, Sihui City

• Tax NO.:

  914412006824906322

• Registered Funds:

  100 million yuan

• Website:

  Log in to view

• Email:

  Log in to view